Assessment of asprosin level and some of physiological variables in patients with cardiovascular diseases in Kirkuk city, Iraq


  • Elaf Erfan Khalaf Al-Hadidi
  • Wedad Mahmood Lahmood Al-Obaidi



Atherosclerosis, myocardial infarction, asprosin, lipid profile, CPK-MB, cardiac troponin , HbA1c


Introduction and Aim: Asprosin is a novel fasting-induced glucogenic adipokine, which stimulates the liver to release glucose into the blood stream. The aim of this study was to examine the role of asprosin as well as various physiological and oxidative stress factors in atherosclerosis and myocardial infarction patients in comparison to healthy controls in Kirkuk city, in order to clarify whether asprosin helps in protecting heart and preventing heart disease.


Materials and Methods: This study included blood samples collected from patients (n=70) and normal healthy controls (n=20), aged between 45-65 years from the Kirkuk General Hospital and external specialized clinical between December 2021 to February 2022. The samples were divided into three groups which included healthy controls (n=20), patients suffering from atherosclerosis (n=40) and myocardial infarction (n=30) respectively. Individuals in all groups were tested for their blood ASP, CPK-BM Tnt and lipid profile levels. Blood serum was also tested for concentration of FBS, INS, HbA1c, MDA and GSH.


Results: The asprosin, CPK-BM, Cardiac troponin (TNt) and INS levels was observed to be significantly elevated in atherosclerosis patients in comparison to healthy controls. However, in myocardial infarction patients significant increase levels was seen only for CPK-BM and INS levels. Lipid profiling showed that except for HDL levels, significant increased levels for TC, TG, LDL and VLDL in both atherosclerosis and MI patients as compared to healthy individuals. The concentration of FBS was seen elevated in blood serum of atherosclerosis and MI patients in comparison to controls.  No significant increase was observed for HbA1c and oxidative stress hormones MDA and GSH).


Conclusion: Changes in asprosin levels in patients with cardiovascular disease could be considered as a biochemical marker to estimate the severity of injury in heart and heart muscles.

Author Biographies

Elaf Erfan Khalaf Al-Hadidi

Department of Biology, College of Science, University of Kirkuk, Iraq

Wedad Mahmood Lahmood Al-Obaidi

Department of Biology, College of Science, University of Kirkuk, Iraq


Yusuf, S., Reddy, S., Ounpuu, S. Anand, S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104(22):2746-2753. DOI:

Alnajjar, M.K., Abu-Naser, S. S. Heart sounds analysis and classification for cardiovascular diseases diagnosis using deep learning, Int. J. Aca. Eng. Res. 2022; 6(1):7-23.

Moradi, N., Fouani, F. Z., Vatannejad, A., Bakhti Arani, A., Shahrzad, S., Fadaei, R. Serum levels of aprosin in patients diagnosed with coronary artery disease (CAD): a case-control study. Lipids Health Dis. 2021; 20(1):1-8. DOI:

Boua, P.R., Brandenburg, J.T., Choudhury, A., Sorgho, H., Nonterah, E.A., Agongo, G., et al., Genetic associations with carotid intima-media thickness link to atherosclerosis with sex-specific effects in sub-Saharan Africans. Nat Commun. 2022; 13(1):1-11. DOI:

Fuster, J.J., MacLauchlan, S., Zuriaga, M.A., Polackal, M.N., Ostriker, A.C., Chakraborty, R., et al., 2017. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science, 2017; 355(6327): 842-847. DOI:

De Lemos, J. A., Drazner, M. H., Omland, T., Ayers, C. R., Khera, A., Rohatgi, A., et al., Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. Jama. 2010; 304(22): 2503-2512. DOI:

Aydin, S., Ugur, K., Aydin, S., Sahin, I. and Yardim, M. Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag. 2019;15 (1): 1-10. DOI:

Ugur, K., Aydin, S. Saliva and blood asprosin hormone concentration associated with obesity. Int. J Endocrinol 2019. Article ID 2521096. DOI:

You, M., Liu, Y., Wang, B., Li, L., Zhang, H., He, H., et al., Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease. Cardiovasc Diabetol 2022; 21(1): 1-15. DOI:

Shabir, K., Brown, J. E., Afzal, I., Gharanei, S., Weickert, M. O., Barber, T. M., et al., Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence. Cytokine Growth Factor Rev. 2021; 60: 120-132. DOI:

Yuan, M., Li, W., Zhu, Y., Yu, B., Wu, J. Asprosin: a novel player in metabolic diseases. Front Endocrinol. 2020; 11: 64. DOI:

Sedlak,J., Lindsay,R. H. Analytical biochemistry. 1968; 25: 192-205. DOI:

Alobaidi, M.B.A., Al-Samarrai, R.R.H. Correlation between serum asprosin level and oxidative stress in Iraqi patients with type II diabetes mellitus. Sys Rev Pharm 2020;11(12):1729-1733.

Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al., Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566–579. DOI:

Wen, M. S., Wang, C. Y., Yeh, J. K., Chen, C. C., Tsai, M. L., Ho, M. Y., et al., The role of asprosin in patients with dilated cardiomyopathy. BMC Cardiovasc Disord. 2020; 20(1): 1-8. DOI:

Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I, Mehmet C, Taner CE. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35:220–223. DOI:

Wang M, Yin C, Wang L, Liu Y, Li H, Li M, Yi X, Xiao Y. Serum Asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 2019;75:205–212. DOI:

Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2017;489:183–188. DOI:

Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocri- nol. 2019; 486:96–104. DOI:

Ben-Yehuda, O., Chen, S., Redfors, B., McAndrew, T., Crowley, A., Kosmidou, I., et al., Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. Euro Heart J. 2019; 40(24): 1930-1941. DOI:

Mazur-Bialy, A. I. Asprosin- A fasting-induced, glucogenic, and orexigenic adipokine as a new promising player. Will it be a new factor in the treatment of obesity, diabetes, or infertility? A Review of the Literature. Nutrients, 2021; 13(2): 620. DOI:

Hernandez, D., Espejo-Gil, A., Bernal-Lopez, M. R., Mancera Romero, J., Baca-Osorio, A. J., Tinahones, F. J., et al., Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC nephrol. 2013; 14(1):1-7. DOI:




How to Cite

Khalaf Al-Hadidi EE, Al-Obaidi WML. Assessment of asprosin level and some of physiological variables in patients with cardiovascular diseases in Kirkuk city, Iraq. Biomedicine [Internet]. 2022 Nov. 14 [cited 2022 Nov. 27];42(5):973-7. Available from:



Original Research Articles

Plum Analytics